Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
79 studies found for:    PSMA
Show Display Options
Rank Status Study
1 Recruiting 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 68Ga-PSMA
2 Active, not recruiting Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
Condition: Prostate Cancer
Intervention: Drug: Ga-68 labeled HBED-CC PSMA PET imaging
3 Recruiting Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Condition: Prostate Cancer
Intervention: Drug: Ga-68 labeled PSMA-11 PET
4 Recruiting 68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated
Conditions: 68Ga-PSMA HBED-PET/CT;   Prostate Cancer
Intervention: Drug: 68Ga- PSMA
5 Recruiting Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
Condition: Prostate Cancer
Intervention: Drug: Ga-68 labeled PSMA-11 PET
6 Not yet recruiting A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors
Conditions: Prostate-specific Membrane Antigen Positive Tumors;   Prostate Cancer;   Breast Cancer;   Lung Cancer
Intervention: Procedure: [Ga-68]PSMA PET/MR
7 Completed Efficacy of Portion Size Measurement Aids
Conditions: Nutrition Assessment;   Obesity
Intervention: Behavioral: Portion Size Measurement Aids (PSMAs)
8 Completed An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
9 Completed A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
10 Completed Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
11 Completed
Has Results
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
Conditions: GBM;   Glioblastoma Multiforme;   Gliosarcoma
Intervention: Drug: PSMA ADC
12 Recruiting 68Ga-PSMA PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
Conditions: Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
Interventions: Drug: gallium Ga 68-PSMA;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography
13 Enrolling by invitation Correlation Between SUV on 68Ga-HBED-CC-PSMA (DKFZ-11) and Gleason Score in Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT
14 Not yet recruiting 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Conditions: Prostate Adenocarcinoma;   PSA Failure;   Recurrent Prostate Carcinoma
Interventions: Procedure: Computed Tomography;   Radiation: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
15 Suspended Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Monitor Adverse Events
Intervention: Drug: Anti-PSMA Designer T Cells
16 Active, not recruiting 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Condition: Recurrent Prostate Carcinoma
Interventions: Procedure: Computed Tomography;   Radiation: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx);   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography
17 Not yet recruiting Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management
Condition: Prostate Cancers
Intervention: Drug: 68Ga-(HBED-CC)-PSMA
18 Completed Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
19 Recruiting 68Ga-PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
Conditions: Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma
Interventions: Device: Computed Tomography;   Radiation: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC;   Other: Laboratory Biomarker Analysis;   Device: Positron Emission Tomography
20 Enrolling by invitation Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
Condition: Prostatic Neoplasms
Intervention: Drug: (68Ga)PSMA-HBED-CC

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.